Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
W
W
Li
L
L
Lu
L
L
Wang
Z
Z
Wang
A W
AW
Thomson
J J
JJ
Fung
S
S
Qian
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D004306:Dose-Response Relationship, Immunologic; D006084:Graft Rejection / Q000517:prevention & control*; D007111:Immunity, Cellular / Q000187:drug effects; D018664:Interleukin-12 / Q000037:antagonists & inhibitors* / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects; D016031:Liver Transplantation / Q000276:immunology*; D008565:Membrane Proteins / Q000494:pharmacology; D051379:Mice; D008809:Mice, Inbred C3H; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D014184:Transplantation, Homologous
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D008565:Membrane Proteins; C084881:flt3 ligand protein; D018664:Interleukin-12